Drugs / Gammora®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06799650 | Jan → Nov 2025 overdue | post-viral disorder | Federal University of São Paulo | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gammora | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06799650 ↗ |
| Modality | Peptide | “16-mer HIV integrase-derived peptide” NCT06799650 ↗ |
| Route | Subcutaneous | “20 mg of Gammora® in 2mL SC solution” NCT06799650 ↗ |